MedTrace Logo

Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine

NCT03281174 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 343

Last updated 2017-09-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the 5-year Immune Persistence of Inactivated Enterovirus Type 71 (EV71) Vaccine manufactured by Sinovac (Beijing) Biotech Co., Ltd.

Conditions

  • Hand, Foot and Mouth Disease

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yuemei Hu · Jiangsu Provicial Center for Disease Control and Prevention

Eligibility

Min Age
6 Months
Max Age
35 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-20
Primary Completion
2017-05-21
Completion
2017-05-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03281174 on ClinicalTrials.gov